Objective: Lung cancer represents the leading cause of cancer death. EGFR mutations, detected in 10-40% of lung adenocarcinomas, are an essential key to therapeutic management. EGFR-activated mutations comprise mainly deletions in exon 19 and point mutations in exon 21. Although histology is the traditional method of detection, we investigated the role of cytology in EGFR mutations. Study Design: A total of 774 lung cancers were studied for EGFR mutations (676 histological and 98 cytological samples), including 424 adenocarcinomas, 326 non-small cell lung carcinomas not otherwise specified, and 24 squamous cell carcinomas. Results: We had a total of 164 (21.2%) cases of mutations. Common mutations were short in-frame deletions in exon 19 (53.7%) and single-nucleotide substitutions in exon 21 (34.1%); less frequent mutations included single-nucleotide substitutions in exon 18 (3.7%) and in-frame insertions/deletions in exon 20 (8.5%). Histologically, EGFR mutations in exons 19 and 21 occurred in 19.4% and in exons 18 and 20 in 2.2%, while the rates cytologically were 13.3% for exons 19 and 21 and 5.1% for exons 18 and 20. Conclusions: The sensitivity for the detection of EGFR mutations in cytological samples overlaps histology, so the use of cytological material constitutes an adequate approach for treatment selection in patients with locally advanced or metastatic lung cancer.

Keywords:
EGFR mutations, Lung cancer, Lung cytology, Rare mutations
1.
Sharma SV, Bell DW, Settleman J, Haber DA: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-181.
2.
Siegel R, Naishadham D, Jemal A: Cancer statistics. Cancer J Clin 2013;63:11-30.
3.
Mitsudomi T: Advances in target therapy for lung cancer. Jpn J Clin Oncol 2010;40:101-106.
4.
Dearden S, Stevensen J, Wu YL, Blowers D: Mutation incidence and coincidence in non-small cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol 2013;24:2371-2376.
5.
Schmitt FC, Longatto-Filho A, Valent A, Vielh P: Molecular techniques in cytopathology practice. J Clin Pathol 2008;61:258-267.
6.
Schmitt FC, Barroca H: Role of ancillary studies in fine-needle aspiration from selected tumors. Cancer Cytopathol 2012;120:145-160.
7.
Keedy VL, Temin S, Somerfield MR: American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011;29:2121-2127.
8.
Brandao GDA, Brega EF, Spatz A: The role of molecular pathology in non-small-cell lung carcinoma - now and in the future. Curr Oncol 2012;19:S24-S32.
9.
Travis WD, Brambilla E, Noguchi M, et al: International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-285.
10.
Kancha RK, Von Bubnoff N, Peschel C, Duyster J: Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy. Clin Cancer Res 2009;15:460-467.
11.
Masago K, Fujita S, Irisa K, Kim YH, Ichikawa M, Mio T, Mishima M: Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC> ATC in exon 20 (S768I). J Clin Oncol 2010;40:1105-1109.
12.
Balak MN, Gong Y, Riely J, Somwar R, Li AR, Zakowski MF, Chiang A, Yang G, Ouerfelli O, Kris MG, Ladanyi M, Miller VA, Pao W: Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006;21:6494-6501.
13.
Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, Tsuboi M, Tada H, Kuwano H, Mitsudomi T: Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006;12:5764-5769.
14.
Tschekuna J, Disayabutr S: Impact of endobronchial ultrasound guided transbronchial needle aspiration on clinical practice guideline. J Med Assoc Thai 2012;95:S92-S97.
15.
Billah S, Stewart J, Staerkel G, Chen S, Gong Y, Guo M: EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens. Cancer Cytopathol 2011;119:111-117.
16.
Chowdhuri SR, Xi L, Pham TH, Hanson J, Rodriguez-Canales J, Berman A, Rajan A, Giaccone G, Emmert-Buck M, Raffeld M, Filie AC: EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection. Mod Pathol 2012;25:548-555.
17.
Da Cunha Santos G, Saieg MA, Geddie W, Leigh N: EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities. Cancer Cytopathol 2011;119:80-91.
18.
Smouse JH, Cibas ES, Janne PA, Joshi VA, Zou KH, Lindeman NI: EGFR mutations are detected comparably in cytological and surgical pathology specimens of nonsmall cell lung cancer. Cancer Cytopathol 2009;117:67-72.
19.
Savic S, Tapia C, Grilli B, Rufle A, Bihl MP, de Vito Barascud A, Herzog M, Terracciano L, Baty F, Bubendorf L: Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers. Br J Cancer 2008;98:154-160.
20.
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004;50:2129-2139.
21.
Greulich H: Oncogenic transformation by inhibitor-sensitive and resistant EGFR mutants. PLoS Med 2005;2:e313.
22.
Fetsch PA, Simir A, Brosky K, Abati A: Comparison of the 3 commonly used cytologic preparations in effusion immunocytochemistry. Diagn Cytopathol 2001;26:61-66.
23.
Akerman M, Alves VA, Bubendorf L, et al: How technology is reshaping the practice of nongynecologic cytology. Acta Cytol 2007;51:123-152.
24.
Eapen GA, Shah AM, Lei X, Jimenez CA, Morice RC, Yarmus L, Filner J, Ray C, Michaud G, Greenhill SR, Sarkiss M, Casal R, Rice D, Ost DE; American College of Chest Physicians Quality Improvement Registry, Education: Complications, consequences and practice patterns of endobronchial ultrasound-guided transbronchial needle aspiration: results of the AQuIRE registry. Chest 2013;143:1044-1053.
25.
Aisner DL, Deshpande C, Baloch Z, Watt CD, Litzky LA, Malhotra B, Sepulveda AR, Langer C, Evans T, Van Deerlin VM: Evaluation of EGFR mutation status in cytology specimens: an institutional experience. Diagn Cytopathol 2013;41:316-323.
26.
Smith GD, Chadwick BE, Willmore-Payne C, Bentz JS: Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis. J Clin Pathol 2008;61:487-493.
27.
Malapelle U, De Rosa N, Bellevicine C, Rocco D, Vitiello F, Piantedosi FV, Illiano A, Nappi O, Troncone G: EGFR mutations detection on liquid-based cytology: is microscopy still necessary? J Clin Pathol 2012;65:940-944.
28.
Malapelle U, De Rosa N, Rocco D, Bellevicine C, Crispino C, Illiano A, Piantedosi FV, Nappi O, Troncone G: EGFR and KRAS mutations detection on lung cancer liquid-based cytology: a pilot study. J Clin Pathol 2012;65:87-91.
29.
Fadda G, Rossi ED: Liquid-based cytology in fine-needle aspiration biopsies of the thyroid gland. Acta Cytol 2011;55:389-400.
30.
Nomoto K, Tsuta K, Takano T, Fukui T, Fukui T, Yokozawa K, Sakamoto H, Yoshida T, Maeshima AM, Shibata T, Furuta K, Ohe Y, Matsuno Y: Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. Am J Clin Pathol 2006;126:608-615.
31.
Wu SG, Gow CH, Yu CJ, Chang YL, Yang CH, Hsu YC, Shih JY, Lee YC, Yang PC: Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma. Eur Respir J 2008;32:924-930.
32.
Powrózek T1, Krawczyk P, Ramlau R, Sura S, Wojas-Krawczyk K, Kucharczyk T, Walczyna B, Szumiło J, Szyszka-Barth K, Milecki P, Barinow-Wojewódzki A, Milanowski J: EGFR gene mutations in patients with adenosquamous lung carcinoma. Asia Pac J Clin Oncol 2014, Epub ahead of print.
33.
Molina-Vila MA, Bertran-Alamillo J, Reguart N, Taron M, Castellà E, Llatjós M, Costa C, Mayo C, Pradas A, Queralt C, Botia M, Pérez-Cano M, Carrasco E, Tomàs M, Mate JL, Moran T, Rosell R: A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells. J Thorac Oncol 2008;3:1224-1235.
34.
Pang B, Matthias D, Ong CW, Dhewar AN, Gupta S, Lim GL, Nga ME, Seet JE, Qasim A, Chin TM, Soo R, Soong R, Salto-Tellez M: The positive impact of cytological specimens for EGFR mutation testing in non-small cell lung cancer: a single south east Asian laboratory's analysis of 670 cases. Cytopathology 2012;23:229-236.
35.
Marchetti A, Del Grammastro M, Filice G, Felicioni L, Rossi G, Graziano P, Sartori G, Leone A, Malatesta S, Iacono M, Guetti L, Viola P, Mucilli F, Cuccurullo F, Buttitta F: Complex mutations and subpopulations of deletions at exon 19 of EGFR in NSCLC revealed by next generation sequencing: potential clinical implications. PLoS One 2012;7:e42164.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.